实用肝脏病杂志2011，Vol.14Issue(1)：31-32,62,3.DOI:10.3969/j.issn.1672-5069.2011.01.011
替比夫定治疗活动性乙型肝炎肝硬化疗效观察
Therapeutic effect of telbivudine on patients with active cirrhosis resulting from hepatitis B
李儒贵 1谭华炳 1占国清 1李芳 1谢杏榕 1李刚1
作者信息
- 1. 442000,湖北省十堰市,湖北医药学院附属人民医院肝病治疗中心
- 折叠
摘要
Abstract
Objective To investigate the efficacy and safety of telbivudine and lamivudine in treatment of active cirrhosis resulting from chronic hepatitis B. Methods 65 patients with active cirrhosis resulting from hepatitis B were randomly divided into treatment group (30 cases)and control group (35 cases). The treatment group received telbivudine 600 mg once daily and the control group received lamivudine 100 mg once daily on the basis of routine treatment for 72 weeks. Results Serum HBV DNA levels decreased,liver function improved,and the Child-Pugh scores lowered(P＜0.05 or P＜0.01)in both groups after the treatment;ALT normalization,HBV DNA and HBeAg loss in treatment group were 83.3％,86.7％ and 44.4％,respectively,while they were 68.6％,68.6％ and 35.0％ in control (P＞0.05). Conclusion Telbivudine can inhibit HBV replication and improve liver function in patients with active cirrhosis resulting from hepatitis B.关键词
乙型肝炎/肝硬化/替比夫定/拉米夫定/治疗引用本文复制引用
李儒贵,谭华炳,占国清,李芳,谢杏榕,李刚..替比夫定治疗活动性乙型肝炎肝硬化疗效观察[J].实用肝脏病杂志,2011,14(1):31-32,62,3.
